QNCX Quince: ערך חשבונאי למניה

The aggregate book value per share correlates with the image of Quince Therapeutics (QNCX) as an innovator in the therapy of rare pathologies, while the value of -34.45 describes the current level. The business foundation is based on compliance with bioethics and environmental ESG standards. The technical base relies on the pristine condition of the laboratories, where equipment for processing cell batches is strictly calibrated.

The development of the AOD platform and the clinical successes of Quince Therapeutics (QNCX) in treating metabolic syndromes directly impact asset capitalization, as reflected by the book value per share metric. This indicator is calculated as the difference between total assets and liabilities divided by the number of shares, allowing investors to assess the real value of their ownership stake in the business net of all debt.